Why FDA’s New Guidance on Circulating Tumor DNA is Critical for Oncology Early Clinical Drug Development
2022 is shaping up to be the “year of the guidance” as the FDA has just released a new guidance on using circulating tumor DNA in early clinical drug development. In this blog, I will reflect on why this agency guidance is so important for new oncology therapeutics. Despite many important advances in oncology drug … Continued